RECEIVED CENTRAL FAX CENTER DEC 2 2 2004

TELEFACSIMILE TRANSMISSION

to

THE UNITED STATES PATENT AND TRADEMARK OFFICE

TO:	Examiner: to be assigned	FROM:	SHELLY GUEST CERMAK
FAX: 703.872.9306		REF. NO:	US-113 ·
VOICE:		PAGES	5 (incl. this sheet)
App. No.:	10/720,169	DATE:	December 22, 2004

The undersigned hereby certifies that the following document(s) is (are) being transmitted by telefacsimile to the United States Patent and Trademark Office at the above "FAX" number, on the above DATE:

- 1) This facsimile cover sheet (1 page)
- 2) Information Disclosure Statement (3 pages)
- 3) PTO-1449 (1 page)

Shelly Guest Cermak

Registration Number 39,571

The information contained in this facsimile message may be privileged, confidential, and protected from disclosure. If you are not the intended recipient, any further disclosure or use, dissemination, distribution, or copying of this message or any attachment is strictly prohibited. If you think that you have received this transmission in error, please destroy it and notify the sender.

Shelly Guest Cermak Registered U.S. Patent Attorney cermaks@ajiusa.com Ajinomoto Corporate Services LLC 1120 Connecticut Ave. Ste. 1010 Washington D.C. 20036 +1 202 457 0284 (v) +1 202 457 0107 (f)

Att'y Dkt. No. US-113 U.S. App. No. 10/720169

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re A	oplication of:		RECEIVED CENTRAL FAX CENTER
	Murata et al.	Art Unit: 1614	DEC 2 2 2004
Appl. N	No.: 10/720,169	Examiner: to be assigned	l
Filing I	Date: November 25, 2003	Atty. Docket: US-113	
	DRUG PRODUCT FOR INTESTINAL DISEASES		
	INFORMATION DISCLOSUS	RE STATEMENT	
Commis P.O. Bo Alexand Sir: examina 1.97 and informati	dria, VA 22313-1450 Listed on the accompanying Form PTO-1449 are documnation of this application, in compliance with the duty of decimals.	of the claimed invention ove tion may not be prior art, and ffered.	er any of the for to prove that this has been made, or
Examin	re does not exist information more material to the examiner is specifically requested not to rely solely on the material Examiner will review art of record in all 35 U.S.C. § 12	rial submitted herewith. It is	further understood
⊠ 1.	This Information Disclosure Statement is being filed with before the mailing date of a first Office Action on the m	thin three months of the U.S. erits. No certification or fee	filing date OR is required.
2 .	The Information Disclosure Statement is being filed mor AND after the mailing date of the first Office Action on Rejection or Notice of Allowance.	re than three months after the the merits, but before the ma	U.S. filing date iling date of a Final
	a. Below is a certification under 37 C.F.R. b. Attached is my check no in the an in the state of the	amount of \$ in paymer	

Att'y Dkt. No. US-113 U.S. App. No. 10/720169

□ 3.	This Information Disclosure Statement is being filed more than three months after the U.S. filing date and after the mailing date of a Final Rejection or Notice of Allowance, but before payment of the Issue Fee. Applicant hereby Petitions that the Information Disclosure Statement be considered. Attached is my check please charge my Deposit Account No. 50-3077 in the amount of \$180.00 in payment of the fee under 37 C.F.R. § 1.17(p).			
□ 4	Certification(s)	under 37 C.F.R. § 1.97(e):		
	□ a.	I hereby certify that each item of information contained in this Information Disclosure Statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this Information Disclosure Statement. 37 C.F.R. § 1.97(e)(1).		
	□ b.	I hereby certify that no item of information on this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application or, to my knowledge after making reasonable inquiry, was known to any individual designated in 37 C.F.R. § 1.56(c) more than three months prior to the filing of this Information Disclosure Statement. 37 C.F.R. § 1.97(e)(2).		
□ 5.	Relevance of the non-English language document(s) is discussed in the present specification. See pages of the specification of the present application.			
□ 6.	The document(s) was/were cited in a corresponding foreign application; a copy of a search report issued in the foreign application is attached, and/or an English language version of the foreign search report is attached for the Examiner's information. M.P.E.P. § 609 III (A)(3).			
7.	A concise explanation of the relevance or a direct translation of the non-English language document(s) is attached hereto or appears below.			
⊠ 8.	One or more of the items of information on this Information Disclosure Statement consitute a related patent application. It has been determined by viewing Private PAIRS that these related patent applications are available to the Examiner through the USPTO's Image File Wrapper System (IFW), and therefore, a copy or copies of the specification, including claims, and drawings have not been provided, in accordance with the "Waiver of the Copy Requirement in 37 C.F.R. §1.98 for Cited pending U.S. Patent Applications" issued September 21, 2004. If the related patent applications are not available via the IFW, a copy or copies are provided herewith. If these applications are published, the citation is to the Publication Number. The identification of this (these) U.S. Patent Application(s) is not to be construed as a waiver of secrecy as to that application(s) now or upon issuance of the present application as a patent. The Examiner is respectfully requested to consider the cited application and the art cited therein during examination.			
□ 9.	Copies of the documents were cited by or submitted to the Office in Application No, filed, which is relied upon for an earlier filing date under 35 U.S.C. § 120. Thus, copies of these documents are not attached. 37 C.F.R. § 1.98(d).			

Att'y Dkt. No. US-113 U.S. App. No. 10/720169

□ 10.	Copies of the documents cited in the International Search Report (PCT/ISA/210) and/or the International
	Preliminary Examination Report (PCT/IPEA/416) have been received by the U.S. P.T.O., as indicated on
	the Notification of Acceptance (PCT/DO/EO/903); accordingly, additional copies are not provided
	herewith. M.P.E.P. §§ 609 II, 1892.03(g).

☐ 11. Copies of the U.S. patent documents cited on the PTO-1449 filed herewith are NOT provided, in accordance with <u>Information Disclosure Statements May Be Filed Without Copies of U.S. Patents and Published Applications in Patent Applications filed after June 30, 2003, 1276 Off. Gaz. Pat. Office 55 (August 5, 2003).
</u>

12. Other:	
------------	--

It is respectfully requested that the Examiner initial and return a copy of the enclosed PTO-1449, and to indicate in the official file wrapper of this patent application that the documents have been considered.

Respectfully submitted,

By:

Shelly Guest Cermak Reg. No. 39,571

Date: December 22, 2004

U.S. P.T.O. Customer Number 38108

Ajinomoto Corporate Services LLC 1120 Connecticut Ave., Ste. 1010 Washington D.C. 20036 202 457 0284

						Page 1 of
FORM PTO 1449		ATTY. DKT. NO.: US-113 APP. NO.: 10/720169		0169		
INFORMATION DISCLOSURE STATEMENT			APPLICANT(S): Murata et al.			
			FILING DATE: 11	-25-2003	Group Art Unit: 1	514
		U.S	. PATENT DOCUMEN	NTS		
EXAMINER INITIAL	DOCUMENT NUMBER	PUB'N DATE	NAME	CLASS	SUB-CLASS	FILING DATE
	2004/0137012	7-15-2004	Murata et al.			11-25-2003
			GN PATENT DOCUM			
EXAMINER INITIAL	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION
						□Yes □ No
						□Yes □ No
						□Yes □ No
						□Yes □ No
						□Yes □ No
··	ОТНЕ	R (Including Auth	or, Title, Date, Pertiner	nt Pages, Publi	sher, etc.)	
		-				
	<u></u>					-

	DATE COMPENSE
EXAMINER	DATE CONSIDERED
•	1

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.